The Food and Drug Administration has accepted for Priority Review a new drug application for baxdrostat, an experimental blood pressure medication for patients with uncontrolled or treatment-resistant hypertension, AstraZeneca announced recently.
If approved, baxdrostat would become the first aldosterone synthase inhibitor indicated for difficult-to-treat high blood pressure, representing a novel therapeutic approach for patients who don’t respond adequately to existing medications.
The FDA’s Priority Review designation, which shortens the standard review timeline from 12 months to 8 months, reflects the significant unmet medical need in hypertension treatment. The company expects a regulatory decision during the second quarter of 2026, following use of a Priority Review voucher.
Baxdrostat is designed as a highly selective, oral inhibitor of aldosterone synthase, an enzyme responsible for producing aldosterone. This hormone regulates sodium and water retention in the body, directly affecting blood pressure levels. By blocking aldosterone production, the drug aims to reduce fluid retention and lower blood pressure through a mechanism distinct from existing treatments.
The FDA submission is supported by results from the BaxHTN Phase III clinical trial, which tested the drug in patients with persistently elevated blood pressure despite treatment with multiple medications. According to AstraZeneca’s clinical data, the study enrolled nearly 800 participants with systolic blood pressure between 140-170 mmHg while taking at least two antihypertensive drugs, or three or more drugs for treatment-resistant cases.
Trial participants were randomly assigned to receive either 1mg or 2mg daily doses of baxdrostat, or placebo, alongside their existing blood pressure medications. The primary measure was change in seated systolic blood pressure after 12 weeks of treatment.
Results showed both doses of baxdrostat produced statistically significant reductions in mean systolic blood pressure compared to placebo, with the higher dose achieving nearly 10 mmHg greater reduction than placebo. This level of blood pressure reduction is considered clinically meaningful, as studies have shown that even modest decreases in systolic pressure can significantly reduce cardiovascular risk.
The need for new hypertension treatments remains substantial. According to the World Health Organization, hypertension affects over 1.3 billion people worldwide and is a leading risk factor for heart disease, stroke, and kidney failure. In the United States, the American Heart Association estimates that nearly half of adults have high blood pressure, and many patients on multiple medications still fail to achieve target blood pressure levels.
Current treatment typically involves combinations of different drug classes, including ACE inhibitors, ARBs (angiotensin receptor blockers), calcium channel blockers, and diuretics. However, approximately 10-15% of hypertensive patients have treatment-resistant hypertension, defined as blood pressure that remains elevated despite optimal doses of three or more antihypertensive drugs from different classes, including a diuretic.
AstraZeneca acquired the rights to baxdrostat through its 2023 purchase of CinCor Pharma, a biotechnology company focused on developing treatments for cardiovascular and renal diseases. The acquisition was part of AstraZeneca’s strategy to expand its cardiovascular portfolio and address significant unmet medical needs.
In the BaxHTN trial, baxdrostat demonstrated what the company characterized as a favorable safety profile. Most adverse events reported were mild, and investigators noted no unexpected safety concerns beyond those anticipated based on the drug’s mechanism of action. The selective nature of the aldosterone synthase inhibition may contribute to its tolerability compared to broader-acting medications.
The drug’s development represents part of ongoing efforts to find new approaches to treating resistant hypertension. Other recent advances have included renal denervation procedures and newer combination therapies, but pharmaceutical options specifically targeting the aldosterone pathway remain limited.
If approved, baxdrostat would likely be positioned as an add-on therapy for patients whose blood pressure remains uncontrolled despite treatment with standard medications. The oral, once-daily dosing could offer convenience advantages for patients already managing complex medication regimens.
The cardiovascular benefits of achieving better blood pressure control are well-established. Meta-analyses of clinical trials have shown that each 10 mmHg reduction in systolic blood pressure is associated with approximately 20% lower risk of major cardiovascular events, 27% lower risk of stroke, 28% lower risk of heart failure, and 13% lower risk of all-cause mortality.
For AstraZeneca, successful approval of baxdrostat could establish a significant market presence in the large hypertension treatment space. The company has indicated that the substantial unmet need among patients with difficult-to-control blood pressure represents a major commercial opportunity.
Beyond the current filing for uncontrolled and treatment-resistant hypertension, future development could potentially explore baxdrostat’s role in broader hypertensive populations or in combination with other cardiovascular therapies, pending regulatory approval and additional clinical evidence.
The FDA’s decision on baxdrostat is expected to be closely watched by cardiologists, primary care physicians, and the millions of patients struggling with inadequately controlled high blood pressure despite current treatment options.